Sugi Predict

Sugi Predict / Compounds / Acetic Acid

Acetic Acid

Acetic Acid

SCHEMBL1628644

CC(=O)O.Cc1ccc(CN)c(NS(C)(=O)=O)c1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NEU3 Q9UQ49 1/20 0.41
▸ NR3C1 P04150 1/20 0.40
▸ PTK2 Q05397 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ADRB3 P13945 3/20 0.39
▸ KMT2A Q03164 2/20 0.37
▸ PTPN2 P17706 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ ACLY P53396 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ METAP2 P50579 1/20 0.37
▸ BRPF1 P55201 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409787 0.92 NR3C1 (0.41) NR3C1PTK2ALDH1A1KDM4EHPGD
Acetic Acid SCHEMBL1627791 0.80 KMT2A (0.50) NR3C1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL1625918 0.80 CYP19A1 (0.45) NR3C1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2185855 0.75 NR3C1 (0.42) NR3C1ALDH1A1ADRB3
Acetic Acid SCHEMBL4593833 0.73 KDM4E (0.46) NEU3NR3C1ALDH1A1KDM4EHPGD
SCHEMBL7556102 0.73 ACLY (0.62) NEU3ALDH1A1KDM4EHPGDHSD17B10
Acetic Acid SCHEMBL1627022 0.72 PTK2 (0.40) PTK2ALDH1A1KDM4EHPGDKMT2A
Acetic Acid SCHEMBL30812944 0.72 ALKBH5 (0.36) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL13303941 0.71 PTGS1 (0.47) NR3C1HPGD
SCHEMBL19420697 0.71 TP53 (0.45) NR3C1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2025-07-03 — — US disclosed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 — — US disclosed
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2022-08-11 — — US disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 — — US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 — — US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 — — US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 — — US disclosed
EP-2146779-B1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2016-08-10 — — EP disclosed
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2016-05-12 — — US disclosed
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH VERASTEM, INC. (US) 2015-03-19 — — US disclosed
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH LUZZIO MICHAEL JOSEPH (US) 2014-04-10 — — US disclosed
US-8440822-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. 2013-05-14 — — US disclosed
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER, INC. 2013-01-03 — — US disclosed
US-8247411-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2012-08-21 — — US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 — — US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 — — US disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20140100368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20150080368-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20130005964-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20160130250-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR NEU3 3586/4885NR3C1 4207/4885PTK2 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.